Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of petosemtamab plus pembrolizumab versus pembrolizumab in first-line PD-L1-positive recurrent/metastatic HNSCC
MOH_2024-07-15_013527Phase 3Not yet recruiting
- Sponsor
- Merus
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Petosemtamab + pembrolizumab with Pembrolizumab (2 arms). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
petosemtamabpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2024-07-15_013527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-15_013527.